Dear CFAR Community:
Today, I want to wish the UCSF-Bay Area Center for AIDS Research (CFAR) a very happy Valentine’s Day. This time last year, we had such high hopes for the pandemic as three highly effective vaccines had just been authorized in the United States. However, it has been an eventful year with the COVID-19 pandemic with not only the variants but the more limited uptake of the vaccines than anticipated in the US. With highly effective (and now more available) oral therapeutics, we have a better way to protect the unvaccinated and advances are continuing in the pandemic. There are multiple initiatives for Global Vaccine and Treatment Equity circulating and we encourage signing on to one or more of these initiatives, such as Medical Professionals for Global Vaccine Equity.
In the HIV world, there has been great advances in HIV medicine—such as the approval of injectable treatments (intramuscular cabotegravir and rilpivirine) and prevention (injectable cabotegravir) this year. There have been setbacks in the HIV response due to COVID-19 with cities around the world showing decreases in virologic suppression or testing with COVID-19 pandemic, including San Francisco. We in the HIV community stand committed to “take back HIV” and rejuvenate testing, prevention and treatment in HIV. For example, Ward 86 worked hard to institute a multi-component strategy to reverse trends in falling virologic suppression rates after the onset of the COVID-19 pandemic and succeeded with increasing in-person care, housing referrals and increasing our social worker services.
Finally, the basic science community has done amazing work on the intersection between HIV and COVID-19, both informing new COVID-19 therapeutics and most recently, a new vaccine candidate involving mRNA technology for HIV (with a human trial just launched). UCSF has contributed greatly to the efforts around HIV and HIV/COVID-19 interactions in the past two years and we are proud of the CFAR investigators who have continued to advance these fields.
CFAR renewal process and outcome:
I took on the Directorship of the CFAR at UCSF in July 2019 working closely with Lauren Sterling (Associate Director) and appointing two co-directors: Mallory Johnson PhD (socio-behavioral science) and Peter Hunt MD (translational/basic science). From July 2019 to October 2019 (before the pandemic so in-person), we met with leaders of the Departments, Divisions, and organizations across the CFAR in order to help determine needed CFAR refinements and expansions to inform renewal planning. In total, we conducted 20 listening sessions with key stakeholders spanning the range of HIV research endeavors. These conversations were structured, and answers recorded systematically as part of a strategic planning process. Many changes were made in direct response to discussions held during these stakeholder conversations, including activities to unify our community, coordinate research collaborations, provide smaller research grants in addition to the larger pilot awards, enhance communication, and bring a new HIV prevention focus to our CFAR. The result was a reconfigured CFAR from UCSF (called the UCSF-Bay Area CFAR) which we submitted to the NIH as a renewal application in July 2021.
In terms of the new structure of the CFAR, in this renewal, we proposed three scientific cores (Clinical, Basic/Translational, Bio-Behavioral), each with 3 constituent components. Our bedrocks of the Administrative and Developmental Core remained intact.
The new Clinical Core (led by Drs. Deeks and Christopoulos) will support the pre-existing SCOPE cohort; a new initiative to increase the diversity of participants in studies across the CFAR by recruiting from Ward 86, which serves vulnerable and low-income patients with HIV (the Participant Referral Service); and Specimen Processing and Banking (AIDS Specimen Bank). With support from CFAR, (which continues to be its primary stable funding base), SCOPE was initiated in 2001 and has since enrolled over 2200 participants with HIV (PWH) and HIV-noninfected controls. SCOPE has been a rich source of data and publications for local, national, and international investigators since its inception.
The Basic/Translational Core (led by Dr. Hunt) will have three components: the Immunology and Functional Genomics Sub-Core, the Pharmacology of Cure and Pathogenesis Sub-Core and a new Bio-informatics Sub-Core. The Immunology and Functional Genomics Sub-Core will continue to be a unique and integral component of our translational research infrastructure: To support the breadth of basic science/translational HIV research across the CFAR. The Pharmacology of Cure and Co-Infections core will continue to support new initiatives in basic science. A Bioinformatics Sub-Core will be added to support investigators in computational high-dimensional data processing, analysis, visualization, and management of multi-omic data.
The Bio-Behavioral Core (led by Mallory Johnson) is new to the CFAR and will provide services identified in our stakeholder conversations that complement, but do not duplicate, functions of CAPS by starting a new PrEP cohort; providing expertise in Substance Use research; and starting a new Biomarkers of Behavior Sub-Core to provide objective measures of adherence and substance use for CFAR investigators.
Each of our Scientific Cores, upon the platform of the Administrative and Developmental Cores, will engage the CFAR membership via a robust array of services, methodological expertise, and assay development and provision when relevant. Our Cores directly support NIH research priorities for HIV, including reducing the incidence of HIV, conducting research towards HIV cure, addressing HIV-associated comorbidities, coinfections, and complications, developing next-generation HIV therapies, and advancing cross-cutting areas of research in the basic sciences, behavioral and social sciences, epidemiology, implementation science, information dissemination, and research training.
We have two new scientific working groups—Housing and Intersectionality—and our three cross-cutting areas of a) Health Equity and Community Engagement; 2) Training and Career Development; and 3) International Research developed from our strategic planning and will further help support Office of AIDS Research (OAR)-established HIV/AIDS research priorities for the NIH.Finally, Dr. Carina Marquez will serve as the overall Equity lead of the CFAR and Drs. John Sauceda and Jonathan Fuchs will continue co-directing the mentorship program.
We are very excited to report that the UCSF-Bay Area CFAR Renewal application in 2021
received a great overall impact score of “10” from the NIH so we will be renewed. We are looking forward to the next five years with you!
I want to thank everyone who helped write the CFAR application, including Lauren, Mallory, Peter, with contributions from all the Core and Sub-Core Directors, the IAB, our mentoring and equity leaders, and all the junior investigators whom I emailed and said please please comb through this- any mistakes? I am so grateful and honored to be serving in this role at the CFAR and very Happy Valentine’s Day to you all (since the CFAR is pretty much my Valentine but that is okay; that is GOOD).
CFAR Administration Update
Rado is originally from South Korea. She has a bachelor's degree in English from UC Berkeley. In her spare time, she likes to go on rigorous hikes, learn to draw better, and play with her 2yo cat named Spock.
Call for CFAR IAB Member-At-Large: Applications Due 4/5
We are now soliciting accepting applications for our open Member-at-Large position of the UCSF CFAR Internal Advisory Board.
Learn More and Apply Here
CFAR and CAPS both received funding for DEI training initiatives
CFAR Scholars Program The CFAR Scholars Program is an internship program for undergrad/grad students from SFSU to gain mentored research opportunities at UCSF through our CFAR. We encourage any San Francisco State University undergraduate or graduate students interested in HIV research to apply. Applications due 3/1.
CAPS Ujima Program The Ujima Program provides multidisciplinary research mentoring and funding to early-stage investigators, particularly those at Historically Black Colleges and Universities (HBCUs), who focus their programs of research on high priority areas that address HIV prevention, care, and treatment in Black/African American communities. Applications due 3/1
Upcoming CFAR Seminars
We’ve continued our CFAR seminar series with exceptional talks from Drs. Barney Graham, Larry Corey, Paul Sax, Katharine Bar, and Mina Hosseinipour this year. If you missed any of their sessions, you can check them out on our YouTube channel. The remainder of our seminars for this year will include Dr. Connie Celum from UW discussing PrEP and women with a Spotlight on the School of Nursing following the talk (March 2), Dr. Carlos Del Rio from Emory University will join us on April 6 to discuss his work on HIV and COVID-19 during both pandemics. His talk will be followed by the presentation of our CFAR Excellence Awards with talks by our awardees (don't forget to nominate Excellence Awardees by 2/25), Dr. Ann Ginsberg from the Gates Foundation will speak next on TB and vaccines with a spotlight on the Division of Experimental Medicine following her seminar (May 4), jointly sponsored by the UCSF Center for TB. And, finally, Dr. José Bauermeister from UPenn will join us for the final seminar of the year to discuss his work on decreasing sexuality-related disparities in young sexual and gender minority groups (June 1). Email email@example.com if you’re not receiving the calendar invites!
Welcome New Faculty
Congratulations to Recent CFAR and NIH K and First-time R01 Awardees!
Mentored Scientist Award to Bharath Sreekumar, Gladstone Institutes: Characterization and assessment of telomerase transduced primary CD4+ T-cells as a model to study HIV latency
Mentored Scientist Award to Miranda Hill, UCSF CAPS/DPS: A examination of the intersection between mobility and HIV outcomes among Black cisgender and transgender women in Atlanta
Mentored Scientist Award to Hannah Leslie, UCSF CAPS/DPS: Identifying clinic factors that shape population health outcomes in times of crisis
Mentored Scientist Award to Sarah Gutin, UCSF CAPS/DPS: Development of novel scales to measure HIV-specific social support for safer conception and male involvement in safer conception approaches for the prevention of HIV
International Mentored Scientist Award to Phoebe Mbabazi, Infectious Diseases Institute: Prevalence, clinical and immunological predictors of frailty among older adults with HIV in Kampala
International Mentored Scientist Award to Khamisi Musanje, Makerere University: Adaptation of a Mindfulness based intervention to support Adherence to Antiretroviral Therapy among adolescents in Uganda
NIH K and First-time R01 Awardees
Christopher Berger, UCSF Pulmonary, K23 HL156784: Digital adherence technologies to facilitate completion of short-course tuberculosis preventive therapy among people living with HIV
Alison Comfort, UCSF Bixby/OB/GYN, K01 HD105521: Understanding individual- and social network-level factors affecting infant HIV testing to design social network interventions to increase testing of HIV-exposed infants
Amelia Deitchman, UCSF Clinical Pharmacy, K23 AI162249: Clinical Pharmacology Approaches towards Accelerating HIV Cure Initiatives
Andrew Kerkhoff, UCSF HIVIDGM, K23 AI157914: Feasibility and acceptability of a peer-led strategy to improve community tuberculosis case finding among non-household contacts in Zambia
Anthony Muiru, UCSF Nephrology, K23 DK119562: SEARCH-CKD: The nature of chronic kidney disease and elevated blood pressure in sub-Saharan Africa.
Michael Peluso, UCSF HIVIDGM, K23 AI157875: Characterizing the virologic and immunologic signatures of HIV exceptional control
Sean Arayasirikul, UCSF Epidemiology and Biostatistics, DP2 AI164315: One Ballroom
Jenny Liu, UCSF SON Institute for Health & Aging, R01 MH124516: AmbassADDOrs for Health: Supporting young women's health through girl-friendly drug vendors
Rachel Rutishauser, UCSF DEM, R01 AI170239: Targeting HIV-specific T cell differentiation programs to enhance post-treatment control of HIV